BR0012556A - Genes e vacinas de ehrlichia canis - Google Patents

Genes e vacinas de ehrlichia canis

Info

Publication number
BR0012556A
BR0012556A BR0012556-3A BR0012556A BR0012556A BR 0012556 A BR0012556 A BR 0012556A BR 0012556 A BR0012556 A BR 0012556A BR 0012556 A BR0012556 A BR 0012556A
Authority
BR
Brazil
Prior art keywords
vaccine
vaccines
ehrlichia canis
genes
proteins
Prior art date
Application number
BR0012556-3A
Other languages
English (en)
Inventor
Yung-Fu Chang
Original Assignee
Cornell Res Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell Res Foundation Inc filed Critical Cornell Res Foundation Inc
Publication of BR0012556A publication Critical patent/BR0012556A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0053—Oxidoreductases (1.) acting on a heme group of donors (1.9)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/29—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Richettsiales (O)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"GENES E VACINAS DE EHRLICHIA CANIS". Essa invenção fornece a seq³ência de 5.300 nucleotídeos do genoma de E. canis. Existem quatro proteínas, ProA, ProB, ORF e um homólogo de citocromo oxidase, assim como um homólogo de peptidase de sinal de lipoproteína parcial no terminal carbóxi, codificada nesse fragmento clonado, As propriedades antigênica, dessas proteínas lhes permitem serem usadas para criar uma vacina. Uma concretização dessa invenção inclui a criação de uma vacina de ADN, uma vacina recombinante e uma vacina de epítopos de células T.
BR0012556-3A 1999-07-21 2000-07-20 Genes e vacinas de ehrlichia canis BR0012556A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35832299A 1999-07-21 1999-07-21
PCT/US2000/019763 WO2001007625A2 (en) 1999-07-21 2000-07-20 Ehrlichia canis genes and vaccines

Publications (1)

Publication Number Publication Date
BR0012556A true BR0012556A (pt) 2002-07-02

Family

ID=23409210

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0012556-3A BR0012556A (pt) 1999-07-21 2000-07-20 Genes e vacinas de ehrlichia canis

Country Status (12)

Country Link
EP (1) EP1210438A2 (pt)
JP (1) JP2003505087A (pt)
CN (1) CN1367832A (pt)
AU (1) AU772946B2 (pt)
BR (1) BR0012556A (pt)
CA (1) CA2375650A1 (pt)
CZ (1) CZ2002601A3 (pt)
HK (1) HK1050708A1 (pt)
IL (1) IL147733A0 (pt)
MX (1) MXPA02000748A (pt)
WO (1) WO2001007625A2 (pt)
ZA (1) ZA200200035B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7335754B2 (en) 1999-07-21 2008-02-26 Cornell Research Foundation, Inc. Ehrlichia canis genes and vaccines
BR0316102A (pt) 2002-11-07 2005-09-27 Abbott Lab Prótese com múltiplos medicamentos em gotìculas não misturadas discretas
EP1638993A4 (en) * 2003-06-10 2007-05-09 Univ Melbourne IMMUNOMODULATING COMPOSITIONS, APPLICATIONS THEREOF AND METHOD FOR THE PRODUCTION THEREOF
JP6161291B2 (ja) * 2009-11-20 2017-07-12 アバクシス， インコーポレイテッド エールリッヒア抗体の検出のためのペプチド、装置、および方法
BR112015008036B1 (pt) 2012-10-11 2022-09-13 Zoetis Services Llc População de peptídeos isolados, método para detectar em uma amostra um anticorpo, método para diagnosticar erliquiose monocítica e/ou granulocítica, método para detectar a presença de anticorpos e kit
US9442112B2 (en) 2014-04-04 2016-09-13 Abaxis, Inc. Compositions and methods for identifying Ehrlichia species

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025338A (en) * 1996-10-17 2000-02-15 University Of Florida Nucleic acid vaccines against rickettsial diseases and methods of use
US6207169B1 (en) * 1997-03-21 2001-03-27 Corixa Corporation Compounds and methods for the diagnosis and treatment of Ehrlichia infection
WO1998042743A1 (en) * 1997-03-24 1998-10-01 Merial Canine ehrlichiosis immunogenic and diagnostic compositions and methods
DE69841899D1 (de) * 1997-09-19 2010-10-28 Ohio State Res Found Proteine der äusseren membran von ehrlichia chaffeensis

Also Published As

Publication number Publication date
CZ2002601A3 (cs) 2003-04-16
ZA200200035B (en) 2003-10-02
AU6225700A (en) 2001-02-13
AU772946B2 (en) 2004-05-13
MXPA02000748A (es) 2003-07-14
CN1367832A (zh) 2002-09-04
HK1050708A1 (zh) 2003-07-04
WO2001007625A2 (en) 2001-02-01
IL147733A0 (en) 2002-08-14
CA2375650A1 (en) 2001-02-01
WO2001007625A3 (en) 2001-10-11
EP1210438A2 (en) 2002-06-05
JP2003505087A (ja) 2003-02-12

Similar Documents

Publication Publication Date Title
BR0010361A (pt) Seq ências genÈmicas de neisseria e uso destas
KR101196178B1 (ko) Ｈｉｖ 조절/부속 단백질의 융합 단백질
WO2021198706A3 (en) Coronavirus vaccines
MXPA02012352A (es) Vacuna para temblores congenitos en cerdos.
EE05138B1 (et) Rekombinantne MVA viirus ja selle kasutamine, isoleeritud eukarootne rakk, meetod rekombinantse HIV Nef-proteiini valmistamiseks ning vaktsiin
HUP9902710A2 (hu) Rekombináns sertés-poxvírus
DK1425404T3 (da) Vaccinia-MVA-E3L-mutanter og anvendelse deraf
BR0012512A (pt) Genes de calicivìrus felino e vacinas notadamente vacinas recombinadas
WO2003089571A3 (en) Ehrlichia canis genes and vaccines
BR0012556A (pt) Genes e vacinas de ehrlichia canis
ATE346931T1 (de) Clostridium perfringens impfstoff
SG142300A1 (en) Promoters for expression in modified vaccinia virus ankara
JP2023528984A (ja) コロナウイルス病に対する組換え修飾ワクシニアウイルスアンカラ（ｍｖａ）ワクチン
IL164179A0 (en) Expression of genes in modified vaccinia virus ankara by using the cowpox ati promoter
MY182347A (en) Genes encoding major capsid protein l1 of human papilloma virus and use of the same
MX2025010780A (es) Composiciones y metodos moduladores de serpina
AU686000B2 (en) Infectious peritonitis vaccine
PT1962889E (pt) Polipéptido imunogénico formado por péptidos crípticos optimizados provenientes de antigénios tumorais, e suas utilizações
EP1816203A4 (en) FOR CORONAVIRUS-SIMILAR PARTICLES CODING EXPRESSION VECTOR
TR200201081A2 (tr) Zayıflatılmış rekombinant kuduz virüs mutantları ve bu mutantların canlı aşıları
BR0112486A (pt) Poliproteìna, molécula de ácido nucleico, plasmìdeo, vacina recombinante ou vacina atenuada, composição farmacêutica, e, método para imunizar um indivìduo contra hiv
NO20083576L (no) Peptider av regulatoriske eller hjelpeproteiner av HIV, samt sammensetninger og anvendelser derav
BR0318026A (pt) Antìgenos recombinantes do vìrus da hepatite a, e, uso dos antìgenos
NZ737583B2 (en) Recombinant modified vaccinia virus ankara (mva) foot and mouth disease virus (fmdv) vaccine

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 32 DA LPI

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.